ClinicalTrials.gg
RecruitingNCT06326021Updated May 22, 2026

Optimised CD33 (FL-33) CAR T Therapy for Refractory/Relapsed Acute Myeloid Leukaemia

A Phase 1 interventional study of autologous FL-33 CAR T therapy and prior-HSCT donor-derived FL-33 CAR T therapy in Refractory/Relapsed Acute Myeloid Leukaemia, sponsored by Beijing GoBroad Hospital. Recruiting at 4 sites in China. Open to participants aged 1 Year to 70 Years. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Beijing GoBroad Hospital · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Non-randomized
Ages
1 Year to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 473 studies in Leukemia, Myeloid, Acute with a site in China — 264 open to participants now, 289 under way, 40 of them phase 3. Leukemia, Myeloid, Acute · China.

Planned enrollment
305th of 433
27 · median 50
Started
2024
with 67 others
Phase 1
121 of 473
69 open now
Primary completion
2026-06
later than 107 of 288 live
Registered
300th of 473
by date

Among the 473 studies in Leukemia, Myeloid, Acute with a site in China, this one is the 305th largest by planned enrollment of the 433 interventional ones that give a count, is one of 68 that started in 2024, is one of 121 in phase 1, reaches primary completion later than 107 of the 288 other live ones, and was the 300th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

264 of the 473 studies in Leukemia, Myeloid, Acute with a site in China are open now. Recruiting first, the newest first:

259 more — sign in →

All 264 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 1 Year to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 473 studies in Leukemia, Myeloid, Acute with a site in China, or all of them as a file.
02

Study summary

This study is a multi-center, open-label, non-randomised, single-arm phaseⅠclinical trial to explore the safety and efficacy of FL-33 CAR T therapy for refractory/relapsed acute myeloid leukaemia. The primary endpoints are incidence and type of dose limiting toxicity within 21 days of CAR T infusion; total number, incidence and severity of adverse events (AE) 30 days after CAR T infusion. The secondary endpoints are total number, incidence and severity of AEs 30 days to 2 years after CAR T infusion; objective response rate (ORR), complete response rate (CR) and complete response with incomplete haematological recovery (CRi) by dose group at 15, 30 and 90 Days after CAR T Infusion; duration of response (DOR), progression-free survival (PFS), overall survival (OS); pharmacokinetic characteristics. The trial will use BOIN12 design to explore the optimal biological dose (OBD) of FL-33 CAR T cells for refractory/relapsed acute myeloid leukaemia. FL-33 CAR T is set at two dose levels: 5*10\^5 (±20%) CAR-T cells/kg for dose 1 (DL-1) and 1*10\^6 (±20%) CAR-T cells/kg for dose 2 (DL-2), and after the optimal biological dose (OBD) is determined in the dose exploration phase, the dose expansion phase will expand the trial by 6-12 cases at the OBD, enrolling up to 21-27 cases. Enrolment of more than 21 cases can be reported for analysis and the trial will be stopped when enrolment reaches 27 cases.Additionally, an independent observation group was established, comprising two sequential cohorts: a minimum of 3 subjects were enrolled starting from the lowest dose level (DL-1).

03

Conditions studied

  • Refractory/Relapsed Acute Myeloid Leukaemia
04

Who can participate

Ages eligible
1 Year to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who met all the inclusion criteria were eligible for enrolment.

    1. Patients diagnosed with primary resistance acute myeloid leukemia, tumour surface antigen CD33 expression, chemotherapy relapse, extramedullary relapse, persistent residual positivity or relapse/ after haematopoietic stem cell transplantation;
    2. Age 1-70 years old;
    3. No severe allergies;
    4. Physical condition: 0-2 score;
    5. Expected survival ≥ 60 days;
    6. Bone marrow or cerebrospinal fluid tumour cells are positive for CD33 by flow cytometry assay or tumour tissues positive for CD33 by immunohistochemistry (CD33 determination of positivity: flow cytometry: >80% of tumour cells expressing CD33 and MFI similar to normal myeloid cells is considered as full positivity; tumour cells greater than 80% of expression of CD33 but MFI lower than the CD33 expression of normal myeloid cells by 1 log is considered as low expression (dim). Tumour cells with between 20-80% positive CD33 expression are partially expressed; Pathological immunohistochemistry: tumour cells>30% positive are considered to be positively expressed;
    7. Self-aware patients aged 19-70 years are required to voluntarily sign an form in writing; paediatric patients aged 1-7 years can be recruited after their legal representative (guardian) had signed an informed consent form; self-aware paediatric patients aged 8-18 years voluntarily sign an informed consent form in writing, and their legal representative (guardian) are required to sign an informed consent form in writing as well;
    8. Suitable and available allogeneic haematopoietic stem cell transplant donors are required, and allogeneic haematopoietic stem cell transplantation can be performed after receiving FL-33 CAR T treatment.

Exclusion criteria

Exclusion Criteria:

  • Patients who fulfil any of the following criteria may not be enrolled.

    1. Patients with history of HSCT but PBMNC is not available from prior- transplant donor for preparation of CAR T cells and peripheral blood tumour load >30%; patients without history of allogeneic HSCT and peripheral blood tumour load >30%;
    2. Intracranial hypertension or cerebral impaired consciousness;
    3. Symptomatic heart failure or severe arrhythmia;
    4. Symptoms of severe respiratory failure;
    5. With other types of ;
    6. Diffuse intravascular coagulation;
    7. Serum creatinine and/or urea nitrogen ≥ 1.5 times the normal value;
    8. With sepsis or other uncontrollable infection;
    9. Suffering from uncontrollable diabetes mellitus;
    10. Severe mental disorders;
    11. Have significant intracranial lesions on cranial MRI;
    12. Organ transplantation (excluding haematopoietic stem cell transplantation) history;
    13. Female patients (patients of ) with positive blood HCG test;
    14. Hepatitis (including and C) and positive screening for AIDS and syphilis.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
27 participants (estimated)

Study arms

  • Experimental
    Autologous FL-33 CAR T

    Peripheral blood mononuclear cells for the production of FL-33 CAR T cells are collected from patients.

    Drug: autologous FL-33 CAR T therapy

  • Experimental
    Prior-HSCT donor-derived FL-33 CAR T

    Peripheral blood mononuclear cells for the production of FL-33 CAR T cells are collected from prior-HSCT donors.

    Drug: prior-HSCT donor-derived FL-33 CAR T therapy

  • Experimental
    Newly matched donor-derived FL33 CAR T

    Peripheral blood mononuclear cells for the production of FL-33 CAR T cells are collected from newly matched donors.

    Drug: Newly matched donor-derived FL-33 CAR T therapy

  • Experimental
    FL-33-03 CAR T

    The independent observation group, serving as an exploratory arm, will uniformly enroll at least 3 subjects starting from the lowest dose level (DL-1) into Cohort 1 to evaluate the safety and efficacy of FL33-03 CAR-T (with TNFα inhibitor). If the results from this stage meet expectations, at least 3 additional subjects will be enrolled into Cohort 2 to evaluate the safety and efficacy of FL33-03 CAR-T (without TNFα inhibitor) at the same lowest dose level.

    Drug: FL33-03 CAR-T therapy

Interventions

  • Drugautologous FL-33 CAR T therapy

    Autologous FL-33 CAR T cells are infused intravenously.

  • Drugprior-HSCT donor-derived FL-33 CAR T therapy

    Prior-HSCT donor-derived FL-33 CAR T cells are infused intravenously.

  • DrugNewly matched donor-derived FL-33 CAR T therapy

    Newly matched donor-derived FL-33 CAR T cells are infused intravenously

  • DrugFL33-03 CAR-T therapy

    Optimized FL-33-03 CAR-T cells

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicity(DLT)

    Incidence and type of dose-limiting toxicity(DLT) within 21 days of FL-33 CAR T infusion.

    Time frame: 21 days

  2. Adverse events (AEs)

    Total number, incidence and severity of adverse events (AEs) within 30 days of FL-33 CAR T infusion.

    Time frame: 30 days

Secondary outcomes

  1. Long-term Adverse events (AEs)

    Total number, incidence and severity of AEs from 30 days to 2 years after FL-33 CAR T infusion will be recorded.

    Time frame: From 30 days after FL-33 CAR T infusion to 2 years

  2. Objective Response Rate (ORR)

    The assessment of ORR by dose group at 15, 30 and 90 Days after FL-33 CAR T infusion according to National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2024 of Acute myeloid Leukemia.

    Time frame: 15, 30, 90 days

  3. Duration of response (DOR)

    DOR is defined as the date when CR or CRi response criteria are first met to the date of relapse or death caused by AML in the absence of documented relapse.

    Time frame: Up to 2 years

  4. Progression-free survival (PFS)

    PFS is defined as the earliest date of occurrence from the first infusion of FL-33 CAR T cells back into the patient who achieved ORR to the earliest date of death from any cause after relapse or remission.

    Time frame: Up to 2 years

  5. Overall survival (OS)

    OS is defined as the time from FL-33 CAR T infusion to death due to any cause.

    Time frame: Up to 2 years

  6. The persistence of FL-33 CAR T cells

    The persistence of FL-33 CAR T cells in cerebral spinal fluid (CSF) and peripheral blood (PB) will be measured by flowcytometry and quantitative polymerase chain reaction (qPCR).

    Time frame: Up to 2 years

07

Study locations

1 of 4 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Jun 2026, 26 months after the start.

Of 307 non-industry phase 1 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 87. This study's planned 26 months is below that.

Counting every sponsor, half of 489 studies reached it within 49 months; a quarter within 31 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2024
First posted
Mar 22, 2024
StartActual
Apr 2, 2024
Primary completionEst.
Jun 15, 2026
CompletionEst.
Dec 30, 2026
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06326021
Lead sponsor
Beijing GoBroad Hospital
Collaborators
The General Hospital of Western Theater Command, Zhaxin Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, Shanghai Liquan Hospital, Ruijin Hospital
Responsible party
Jing Pan (Director of Dept of Hemato-Oncology and Immunotherapy, Beijing GoBroad Hospital) — Principal investigator
First posted
Mar 22, 2024
Start date
Apr 2, 2024
Primary completion
Jun 15, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
May 22, 2026

Study contacts

Shaocong Miao
Contact
miaosc@gobroadhealthcare.com
86+ 18831006667

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion